Effects of an immuno-enhanced diet containing antioxidants in esophageal cancer surgery following neoadjuvant therapy.
Study Goal
The researchers aimed to determine whether an immuno-enhanced diet containing antioxidants could reduce oxidative stress and improve immune competence in esophageal cancer patients undergoing neoadjuvant therapy and surgery.
Results Summary
The study found that the immuno-enhanced diet reduced oxidative stress post-surgery but did not significantly prevent immunological deterioration caused by neoadjuvant therapy. Antioxidant activity was transiently affected, with lower oxidative stress markers in the diet group compared to controls.
Population
Patients with esophageal cancer undergoing neoadjuvant therapy followed by surgery.
Effective Dosage
Not specified (immuno-enhanced diet administered for 5 days pre-surgery).
Duration
5 days before surgery.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
neoadjuvant therapy | decrease | several immunological parameters | patients with esophageal cancer | - | significantly affected | #1 |
neoadjuvant therapy | decrease | immune competence | patients with esophageal cancer | - | induced immunological deterioration | #2 |
preoperative administration of an immuno-enhanced diet | no change | neoadjuvant therapy-induced immunological deterioration | patients with esophageal cancer | - | did not significantly prevent | #3 |
immuno-enhanced diet containing several antioxidants | decrease | oxidative stress | patients following esophageal cancer surgery | - | may reduce | #4 |
immuno-enhanced diet | decrease | d-ROMs values | group 1 patients | - | were significantly lower | #5 |
immuno-enhanced diet | increase | OXY-adsorbent test values | group 2 patients | - | were significantly higher | #6 |
immuno-enhanced diet | decrease | oxidative index | group 1 patients | - | was significantly suppressed | #7 |
neoadjuvant therapy | decrease | lymphocyte numbers | groups 1 and 2 | - | significant depression | #8 |
neoadjuvant therapy | decrease | numbers of B cells | groups 1 and 2 | - | significantly decreased | #9 |
neoadjuvant therapy | decrease | CD4/CD8 ratio | groups 1 and 2 | - | significantly decreased | #10 |
neoadjuvant therapy | decrease | phytohemagglutinin-induced lymphocyte transformation tests | groups 1 and 2 | - | significantly decreased | #11 |
no enteral feeding products before surgery | increase | fibrin and fibrinogen degradation products | group 2 | - | were significantly elevated | #12 |
- | increase | d-ROMs and OXY-adsorbent test values | patients with esophageal cancer before surgery | - | were elevated | #13 |
- | decrease | d-ROMs and OXY-adsorbent test values | patients with esophageal cancer early after surgery | - | were decreased transiently | #14 |
- | no change | morbidity after surgery | patients with esophageal cancer | - | No significant intergroup differences were observed | #15 |
Neoadjuvant therapy-induced immunological deterioration may be a key factor in postoperative morbidity in patients with esophageal cancer. This study aimed to determine the effects of perioperative feeding with an immuno-enhanced diet on immune competence in patients treated with neoadjuvant therapy followed by surgery. Because an immuno-enhanced diet that contained several antioxidants was used, perioperative oxidative stress and the effects of the immuno-enhanced diet on this stress were also investigated. Of 39 patients with esophageal cancer who underwent similar surgical procedures, 26 patients who received chemotherapy or chemoradiation therapy before surgery were randomly divided into two groups: group 1 (n= 14) was given an immuno-enhanced diet for 5 days before surgery, and group 2 (n= 12) received no enteral feeding products before surgery. Group 3 (n= 13) consisted of patients that did not receive neoadjuvant therapy and received no enteral feeding products before surgery. Several markers for coagulation and fibrinolysis were determined and immunological assessments were performed for each patient. To measure reactive oxygen metabolites and the total antioxidant capacity, diacron-reactive oxygen metabolites (d-ROMs) and OXY-adsorbent tests were performed using a free radical elective evaluator. Significant depression in lymphocyte numbers was observed in groups 1 and 2 before and early after surgery as compared to group 3. Numbers of B cells, CD4/CD8 ratio, and phytohemagglutinin-induced lymphocyte transformation tests were also significantly decreased in groups 1 and 2 on postoperative day 1. Fibrin and fibrinogen degradation products were significantly elevated in group 2 compared to group 1. d-ROMs and OXY-adsorbent test values were elevated before surgery and were decreased transiently early after surgery. Compared to groups 2 and 3, d-ROMs values were significantly lower in group 1 patients throughout the postoperative period, while OXY-adsorbent test values were significantly higher in group 2 patients. Oxidative index was significantly suppressed in group 1 compared to group 3. No significant intergroup differences were observed with regard to morbidity after surgery. Although the baseline levels of immunological function might have been different because of less-advanced cancer stages in group 3, neoadjuvant therapy significantly affected several immunological parameters. Preoperative administration of an immuno-enhanced diet did not significantly prevent neoadjuvant therapy-induced immunological deterioration prior to esophageal cancer surgery. Patients with esophageal cancer had elevated levels of oxidant and antioxidant activities before surgery, which were transiently decreased early after surgery. Although the underlying mechanisms for these perioperative changes are unclear, this study showed that an immuno-enhanced diet containing several antioxidants may reduce oxidative stress following esophageal cancer surgery. After these mechanisms are studied further, oxidative stress control may become another tool for perioperative management to reduce morbidity after esophageal cancer surgery.